Welcome to our dedicated page for Mereo BioPharma Group news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo BioPharma Group stock.
Mereo BioPharma Group plc reports clinical, partnering, and financial developments for a rare-disease biopharmaceutical pipeline traded in the U.S. through ADSs under MREO. Its recurring updates center on setrusumab (UX143) for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2.
Company news also covers trial results and data analyses from the ORBIT and COSMIC studies, orphan and Fast Track regulatory designations for alvelestat, cash runway and operating-expense updates, and collaboration activity involving Ultragenyx, āshibio, and other development partners. Reports link program progress with capital allocation across core and non-core rare-disease assets.
Mereo BioPharma reported its Q1 2024 financial results, showing cash and cash equivalents of $48.7 million. The company expects to fund operations into 2026. Key updates include the completion of enrollment in the Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta by partner Ultragenyx, and ongoing pre-launch activities in Europe. Mereo also announced progress in partnering discussions and research for alvelestat and etigilimab. Financial highlights included a 25% decrease in R&D expenses, a 8% reduction in general and administrative expenses, and a net loss of $9.0 million, compared to $12.1 million in Q1 2023. The company remains focused on advancing its clinical programs and engaging with partners for future developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.